Virax Biolabs Group Ltd VRAX

Healthcare SIC 2835 - In Vitro & In Vivo Diagnostic Substances NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2026 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2026FY2024FY2023FY2022FY2021FY2020FY2019
Operating income —-$6.2M-$6.5M-$5.7M-$1.7M-$644.5K—
Net income —-$6.1M-$6.7M-$5.5M-$1.7M-$672.9K—

Balance sheet

Fiscal year FY2026FY2024FY2023FY2022FY2021FY2020FY2019
Total assets —$6.4M$5.5M$9.8M$48.7K$39.6K—
Total equity —$5.5M$5.1M$8.9M-$1.2M-$831.8K-$1.2M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-295158.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -8M -6M -4M -2M 0 Net income, FY2020: -672.9K Net income, FY2021: -1.7M Net income, FY2022: -5.5M Net income, FY2023: -6.7M Net income, FY2024: -6.1M FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2026
Fiscal year FY2019FY2020FY2021FY2022FY2023FY2024FY2026
Revenue — — — — — — —
Gross profit — — — — — — —
Net income — -$672.9K -$1.7M -$5.5M -$6.7M -$6.1M —

Others in SIC 2835

TickerCompanyMarket capP/ERevenue growth
IDXX IDEXX LABORATORIES INC /DE $44.15B 42.8x 10.4%
LNTH Lantheus Holdings, Inc. $6.51B 29.3x 0.5%
NEOG NEOGEN CORP $2.66B — -2.7%
CLDX Celldex Therapeutics, Inc. $2.30B — -78.0%
NTLA Intellia Therapeutics, Inc. $1.57B — 16.9%
QDEL QuidelOrtho Corp $941.5M — -1.9%
ACHV ACHIEVE LIFE SCIENCES, INC. $667.8M — —
MYGN MYRIAD GENETICS INC $556.7M — -1.6%